» Articles » PMID: 38845836

Oncoplastic Surgery in the USA: a Review of Where We Started, Where We Are Today and Where We Are Headed

Overview
Journal Gland Surg
Specialty Endocrinology
Date 2024 Jun 7
PMID 38845836
Authors
Affiliations
Soon will be listed here.
Abstract

The surgical management of breast cancer has evolved tremendously over the last century and now includes oncoplastic techniques that improve both cosmetic and oncologic outcomes for patients. The purpose of this review is to provide the reader with a broad overview of the history of oncoplastic breast surgery in the United States (USA), and to summarize important patient factors and technical innovations for optimal operative planning in the era of multimodal treatment of breast cancer. The indications for oncoplastic surgery (OPS) have broadened significantly as more women pursue breast conservation with preservation of their native breast tissue. The operative philosophy of OPS is based on fundamental reconstructive principles, with technique selection based largely on tumor size and location. Reduction mammoplasty and mastopexy techniques have become some of the most utilized procedures in OPS due to their versatility to address tumors in almost all areas of the breast. Volume replacement techniques with locoregional perforator flaps continue to gain popularity as a single-stage reconstructive option for women with large tumor to breast ratios, especially with specialized plastic surgeons at high volume, academic centers. The oncologic advantages of OPS have allowed women to avoid mastectomy with improved margin control, re-excision rates, and equivalent overall survival all while preserving the aesthetic outcomes for these patients. Despite the proven benefits of OPS, numerous healthcare systems barriers including insurance status, geographic location, referral patterns, and racial disparities all continue to play a role in access to surgical sub-specialized breast oncology care demonstrating the need for ongoing research and education about oncoplastic principles.

Citing Articles

Pyoderma Gangrenosum: A Nightmare for Breast Surgery-Two Case Reports.

Akoglu G, Demiriz M, Yilmaz K Eur J Breast Health. 2025; 21(1):80-84.

PMID: 39744929 PMC: 11706121. DOI: 10.4274/ejbh.galenos.2024.2024-7-5.

References
1.
Hershman D, Wang X, McBride R, Jacobson J, Grann V, Neugut A . Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int J Radiat Oncol Biol Phys. 2006; 65(5):1353-60. DOI: 10.1016/j.ijrobp.2006.03.048. View

2.
Losken A, Hart A, Broecker J, Styblo T, Carlson G . Oncoplastic Breast Reduction Technique and Outcomes: An Evolution over 20 Years. Plast Reconstr Surg. 2017; 139(4):824e-833e. DOI: 10.1097/PRS.0000000000003226. View

3.
Mattingly A, Ma Z, Smith P, Kiluk J, Khakpour N, Hoover S . Early Postoperative Complications after Oncoplastic Reduction. South Med J. 2017; 110(10):660-666. PMC: 7771341. DOI: 10.14423/SMJ.0000000000000706. View

4.
Chetta M, Aliu O, Zhong L, Sears E, Waljee J, Chung K . Reconstruction of the Irradiated Breast: A National Claims-Based Assessment of Postoperative Morbidity. Plast Reconstr Surg. 2016; 139(4):783-792. PMC: 5373960. DOI: 10.1097/PRS.0000000000003168. View

5.
Piper M, Peled A, Sbitany H, Foster R, Esserman L, Price E . Comparison of Mammographic Findings Following Oncoplastic Mammoplasty and Lumpectomy Without Reconstruction. Ann Surg Oncol. 2015; 23(1):65-71. DOI: 10.1245/s10434-015-4611-3. View